Virtual Lecture on Current and Emerging Perspectives in the Diagnosis and Management of Adult Glioblastoma

OVERVIEW
This CME activity consists of a program overview, a presentation, a learning assessment, and an evaluation form.  Estimated time to complete this activity: 1.25 hours

TARGET AUDIENCE
This activity is designed to meet the educational needs of physicians, pharmacists, and registered nurses involved in the care of adult glioblastoma patients.

STATEMENT OF NEED
While there is no cure for most patients with glioblastoma multiforme (GBM), emerging evidence from recent research offers healthcare providers opportunities to prolong survival and improve patients’ quality of life. Use of the optimal prognostic models to improve the accuracy of disease classification and identify patients with specific genetic markers associated with treatment response to chemotherapy will ensure that patients receive the most efficacious care. In addition, patients require multidisciplinary healthcare teams that collaborate in the development of treatment plans that integrate emerging treatments for newly diagnosed GBM. The high rate of recurrence also establishes the imperative for education of healthcare providers regarding optimal second-line and salvage therapeutic options.

EDUCATIONAL OBJECTIVES
After completing in this educational activity, participants should be able to:
- Summarize the strengths and limitations of current treatments for newly diagnosed and recurrent glioblastoma
- Describe prognostic factors in the survival of adults with glioblastoma
- Identify molecular and genetic biomarkers associated with response to treatment
- Identify emerging targeted treatment alternatives that have demonstrated favorable results in glioblastoma
- Provide appropriate care and counsel for patients and their families

METHOD OF PARTICIPATION
To complete this activity and receive a statement of credit, participants must:
1. Review all contents of this activity
2. Complete and submit the learning assessment and evaluation form
3. Score at least 70% on the learning assessment
4. There are no fees for participating and receiving CME credit for this activity. During the period August 27, 2012 through August 27, 2013, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 8841. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.

PHYSICIAN CONTINUING EDUCATION - ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION - ACCREDITATION STATEMENT
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.1 contact hours (1.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0809-9999-12-323-H01-P)

If you participated in the live activity (Universal Activity Number - 0809-9999-12-183-L01-P), you are not eligible for this activity.

MEDIUM: Internet; TYPE OF ACTIVITY: Knowledge

PHARMACY EDUCATIONAL OBJECTIVE
After completing this activity, the participant should be able to:
• Provide accurate and appropriate counsel as part of the treatment team
---
NURSING CONTINUING EDUCATION - CREDIT DESIGNATION
This educational activity for 1.1 contact hours is provided by Postgraduate Institute for Medicine.

ACCREDITATION STATEMENT
The Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 4 weeks.

NURSING EDUCATIONAL OBJECTIVE
After completing this activity, the participant should be able to:
• Provide appropriate care and counsel for patients and their families
--------------------------------------------------------------------------------
FACULTY
Joachim M. Baehring, MD, DSc
Director, Yale Brain Tumor Center
Associate Professor of Neurology, Medicine and Neurosurgery
Yale University School of Medicine
New Haven, Connecticut
--------------------------------------------------------------------------------
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

- Joachim M. Baehring, MD, DSc, has an affiliation with Sigma-Tau Pharmaceuticals (Speaker’s Bureau).
- The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: RMEI, LLC
- Emma Hitt, PhD, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
--------------------------------------------------------------------------------

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, RMEI, LLC, and Genentech do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, RMEI, LLC, or Genentech. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
--------------------------------------------------------------------------------
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
--------------------------------------------------------------------------------
FEE INFORMATION
There is no fee for this educational activity.